The latest price target for Amicus Therapeutics (NASDAQ:FOLD) was reported by Cantor Fitzgerald on January 15, 2025. The analyst firm set a price target for $21.00 expecting FOLD to rise to within 12 months (a possible 119.21% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Amicus Therapeutics (NASDAQ:FOLD) was provided by Cantor Fitzgerald, and Amicus Therapeutics reiterated their overweight rating.

The last upgrade for Amicus Therapeutics Inc happened on May 14, 2024 when Guggenheim raised their price target to $13. Guggenheim previously had a neutral for Amicus Therapeutics Inc.

The last downgrade for Amicus Therapeutics Inc happened on December 13, 2024 when Morgan Stanley changed their price target from $17 to $12 for Amicus Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on January 15, 2025 so you should expect the next rating to be made available sometime around January 15, 2026.

While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a reiterated with a price target of $21.00 to $21.00. The current price Amicus Therapeutics (FOLD) is trading at is $9.58, which is out of the analyst’s predicted range.